All existing BEVA members will have their membership automatically extended until 30 June 2020. The association is also inviting vets and vet nurses who are not already BEVA members to join as online members free of charge until 30 June 2020.
BEVA President Tim Mair said: “In this extraordinary time of global crisis our profession, as with many industries, is under immense pressure. By offering free membership we are giving equine vets easy access to a wealth of supportive resources and online CPD to help them through these dark times.”
BEVA membership includes:
The association is also looking at other ways to support the profession, which has included making all BEVA Congress 2019 webinars available to members via the BEVA online learning platform.
To sign up from Monday 30 March 2020 visit: https://www.beva.org.uk/Join-BEVA
The Fédération Équestre Internationale (FEI) has added Metacam for Horses to its 'list of detection times'.
According to the manufacturer, Boehringher Ingelheim Vetmedica, Metacam (meloxicam) is the first preferential COX-2 inhibitor to be added to this list, and has stated plasma and urine detection times of 72 hours administered intravenously or orally1. This is the shortest urine detection time of the NSAIDs available for use in horses, and compares to the 168-hour (7 days) detection time for phenylbutazone stated by the FEI.
Craig Beck, equine sales and marketing manager for Boehringer Ingelheim in the UK and Ireland said: "We have been very happy to work in partnership with the FEI to provide the robust data that has supported the FEI in their analysis of Metacam. Metacam is an important addition to the FEI list, that will help vets treating competition horses. There is now a modern and proven NSAID which extends the therapeutic options available to vets."
Metacam is licensed in horses for the alleviation of inflammation and relief of pain associated with musculo-skeletal disorders or colic.
For further information, please contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
1 Detection Time agreed with the European Horse Racing Scientific Liaison Committee (EHSLC)
The guidelines, which have produced by a panel of clinicians and analgesia researchers, summarise the current evidence and offer expert opinion and best practice recommendations for the use of analgesics for common scenarios.
Recommendations include:
Professor Celia Marr, Editor of the EVJ said: "The BEVA primary care clinical guidelines provide up-to-date clarity on the fundamental aspects of equine pain management for the clinician and are essential reading for all those in first opinion ambulatory roles."
The guidelines are the first in a series being produced for primary care vets by BEVA. They can be downloaded here: https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.13198
Tim took over the role from Renate Weller at the end of BEVA Congress last week. Lucy Grieve, of Rossdales Veterinary Surgeons became President Elect.
After leaving Bristol in 1989, Tim worked in mixed practice before joining Bell Equine in 1993, becoming a partner in 1995. He led the hospital services at Bell Equine, as well as supervising the practice’s residency, intern and extern programmes, until it was bought by CVS in 2016. He continues to work as a clinician at Bell Equine whilst also working as the Equine Veterinary Director of CVS.
Tim is an RCVS Specialist in both equine internal medicine and equine soft tissue surgery and is a founding diplomate of the European College of Equine Internal Medicine; he became an Associate of the European College of Veterinary Diagnostic Imaging in 2011. He is an honorary Professor of the Royal Veterinary College and became a Fellow of the RCVS in 2016.
Editor of Equine Veterinary Education, the official journal of the British Equine Veterinary Association and the American Association of Equine Practitioners for the past 23 years, Tim has particular interests in clinical research, clinical standards and evidence based medicine, and has published widely in the professional veterinary literature, as well as authoring and editing several textbooks. He has been a member of the RCVS Practice Standards Group since 2012.
Tim has been chair of BEVA’s Education Committee since 2014, and says that during his presidential year he is keen to continue to develop BEVA’s educational activities for members at all stages of their careers.
In particular, he says he is particularly looking forward to supporting recent graduates in equine practice with relevant CPD and mentoring. He also hopes to advance the use of evidence-based veterinary medicine, and promote quality improvement in equine practice.
Tim said: "Equine practice is continuing to change and evolve with some rapidity. An important part of my focus will be on our Equine Veterinary Horizons Project, looking at anticipated advances over the next 10-15 years, what they will mean to individual practitioners and to practices and how we can adapt to and accommodate them to best advantage."
For further information visit www.beva.org.uk.
Elanco has announced the results of a challenge study which the company says demonstrates the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course1.
The study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two dose of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Richmond/1/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
According to Elanco, this is believed to be the first demonstration of cross protection by a current UK equine influenza vaccine against a Florida sub-lineage clade 2 reference strain.
The OIE (World Organisation for Animal Health) updated its equine influenza vaccine recommendations in 2010 to reflect the fact that all field strains characterised through 2008 and 2009 were of clade 1 or 2 of the Florida sub-lineage. The antigenic difference between viruses of these clades could potentially compromise the effectiveness of vaccines containing a representative of a single clade2.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health, said: "Whilst no vaccine has been updated to match the current OIE recommendations, the results of this challenge study provide reassurance that horses vaccinated with Duvaxyn will be protected against clinical signs of disease caused by currently circulating strains of equine influenza, including those the OIE have identified as being of concern."
Duvaxyn IE-T Plus is an inactivated whole virus equine influenza vaccine, adjuvanted with an aqueous-based adjuvant. Elanco says that experts in the field of human vaccination have expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly-based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins in the vaccine3.
References:
The new tool is part of a package that also includes posters and SMS texts to support veterinary practices in raising awareness of gastric ulcers to horse owners.
Equine Gastric Ulcer Syndrome (EGUS) is a serious and common condition and any type of horse can be at risk.1 EGUS can have a profound impact on a horse’s condition and performance and can be life threatening in foals. It is a challenging condition to diagnose as the clinical signs are often vague and not always present.1
Gastroscopy is the only method currently available for a definitive diagnosis. Of the two types of disease equine squamous gastric disease is graded on a numeric scale with 1 being the least severe and 4 being the most serious. Equine glandular gastric disease can be very varied in terms of location and type so grading this disease on a score system is no longer recommended. Instead it is now usually described in terms of location, severity and appearance.2
The new tool has been designed to help vets to map the area affected by gastric disease and record the details in an accessible format. This information, together with treatment and management recommendations, can be shared easily with the client. Posters explaining gastric ulceration have been designed to help increase awareness and understanding of EGUS amongst horse owners.
Zoetis says effective treatment usually involves a combination of management and medical treatments. UlcerGold is indicated to treat and prevent the recurrence of gastric ulcers in horses, administered once-daily for 28 consecutive days at the full dose of 4mg/kg bodyweight followed by the reduced dose of 1mg/kg bodyweight for a further 28 days.3 It contains omeprazole, a proton pump inhibitor that suppresses gastric acid secretion.3,4 One syringe contains enough UlcerGold for a daily dose for a horse weighing up to 700kg. It can be used for foals as young as four weeks of age that weigh over 70kg and for breeding stallions.
References
The divestment is expected to be concluded in mid-2020, and Bayer intends to exit its stake in Elanco over time.
Bayer says that combining Elanco and Bayer Animal Health will create the number two animal heath company, with top three positions across a broad range of species and geographies. It also enhances Elanco’s portfolio of leading global brands and bolsters its innovation capabilities and R&D pipeline.
Jeffrey N. Simmons, president and chief executive officer of Elanco, said: "Combining Elanco’s strong relationship with veterinarians and Bayer’s leadership in retail and e-commerce will ultimately benefit all our customers. We look forward to joining our complementary portfolios and capabilities to build a fully focused animal health company, providing a sustained flow of innovation for farmers, veterinarians and pet owners."
Practices which want to buy the alternative imported vaccine will need to apply to the VMD for a Special Import Certificate (SIC).
Wholesalers have agreed to stock the alternative vaccine.
Zoetis says it acknowledges the concern and frustration this causes its customers and wants to reassure the equine community that it is working hard to resume Equip Rotavirus supply as soon as possible.
For further information, contact your Zoetis account manager or ring Zoetis HQ on 0345 300 8034.
The Animal Health Trust has cut the first sod of a new cancer centre for animals in Suffolk.
The AHT's Cancer Centre will provide all three treatment options: surgery, chemotherapy and radiotherapy, on one site. The cancer facility is being purpose-built to treat horses, dogs and cats.
Sue Murphy, Head of Clinical Cancer Treatment at the AHT, said: "Having all three treatment options on one site means that whatever the diagnosis, we will be able to offer each and every patient the very best options for their specific case. With one in four dogs and one in six cats developing cancer at some time in their life this new centre will help many more animals - from Suffolk, East Anglia and all across the UK."
The new centre will also further research into cancer. Treating animals with all types of the disease will enable the AHT's vets and scientists to expand current knowledge about cancer. This will help with the development of new ways to diagnose and treat the disease.
Vets and scientists at the AHT already work collaboratively with cancer researchers looking at the disease in humans. There are a number of links between human and animal cancers which have already been identified. It is hoped that knowledge gained from the AHT Cancer Centre may also help in the understanding of cancer in people.
The AHT hopes the building will open in summer 2012 . It is launching an appeal to raise much needed funds to equip the centre with a linear accelerator. This piece of specialist equipment works by delivering high-energy radiation beams to break cancerous tumours down while sparing the surrounding normal tissue.
The AHT Cancer Centre will be one of only six veterinary facilities in the UK to house a linear accelerator.
Sue Murphy added: "Currently, there is no way to tell which animals will, and which animals won't, develop cancer. It could happen to any animal at any time. This new centre will give more animals a fighting chance of beating the disease, enabling them to lead long and healthy lives. The fact that treatments developed to benefit our pets may also lead to improvements in the prevention and treatment of cancer in humans makes this centre all the more important.
"I would urge you to donate whatever you can to help equip the centre. Your donation, however large or small, will help many more animals beat cancer and it may also help in the fight against cancer in people."
If you would like to make a donation to the AHT Cancer Centre please visit www.aht.org.uk or telephone 01638 555648.
Alternatively you can make a £5 donation by textingVETS24 £5 to 70070
The Federation of European Equine Veterinary Associations (FEEVA) and the European Federation of Farriers Associations (EFFA) have announced that they have joined forces to promote best practice in farriery.
The initiative is the result of recognition by both organisations that equine welfare is best served with the use of only properly trained farriers, working closely with veterinary surgeons as and when needed.
The organisations say that the main aims of the new partnership include:
The President of FEEVA, Professor Josh Slater said: "We look forward to working together at European level and encouraging member associations to do the same at national level, with the primary intention of enhancing equine health through first class farriery."
Pfizer Animal Health is offering the chance to win £500 worth of CPD vouchers to UK veterinary surgeons who participate in the company's 5 minute online survey about Equine Herpes Virus (EHV).
Pfizer says the intention of the survey is to find out more about veterinary perceptions and understanding of this endemic disease and its effects on the UK's valuable equine industry. There are five multi-choice questions and the survey is available online from now until 31st May 2012. Vets who show their prowess in the skills-based section of the survey will be entered to win £500 of British Equine Veterinary Association CPD vouchers.
The survey is part of Pfizer's EHV awareness campaign to help vets encourage horse owners, yard managers, trainers and breeders to keep their horses protected from the effects of this common but often under-prioritised disease. The campaign includes the provision of information leaflets and the coordination of talks to help people, who manage horses, understand the severity of EHV and the best ways to prevent it.
According to Pfizer, the prevalence of EHV can be as high as 87.5% in the UK and latent infections in horses are frequently re-activated.1,2 The consequences can be serious, with abortion outbreaks proving to be a significant economic burden to owners, trainers and breeders.3,4 However, subclinical infections, although usually regarded as less serious, can remain unrecognised and can cause suboptimal performance in horses.
Sporadic, mild respiratory disease caused by EHV can lead to interrupted training and movement restrictions.4 Even after clinical recovery from EHV-1 or upper respiratory tract infections caused by EHV-4, some horse may develop 'poor performance syndrome'.5 These can all have serious financial repercussions on the equine industry.
To take part in the survey, visit http://www.ehvaware.com/. For further information on Pfizer's EHV campaign, to obtain literature for your practice or to book a talk for your clients please contact your Pfizer Account Manager.
1. Eddington et al. Equine Vet. J. 1994; 26 (2): 140-142. 2. Allen GP. 2002. Respiratory Infections by Equine Herpesvirus Types 1 and 4. In: P. Lekeux ed. 2002. Equine Respiratory Diseases. New York: International Veterinary Information Service. 3. Garré B et al. Vet Microbiol. 2007; 122(1-2): 43-51. 4. Lunn DP et al. J Vet Intern Med. 2009; 23(3): 450-61. 5. Slater, J. 2007. Equine Herpesvirus. In: Sellon, D. and Long, M. Equine Infectious Diseases. St Louis: Saunders. 144.
A new study published in Equine Veterinary Journal's (EVJ) in partnership with the American Association of Equine Practitioners, has shown that a wireless, inertial sensor-based system can effectively measure a horse's response to a flexion test.
The authors say that opinions on the value of flexion tests in assessing equine lameness have been divided for many years, but their research should turn what has always been regarded as a subjective process into a wholly objective one.
Flexion tests are used routinely in horses with subtle or imperceptible lameness, to exacerbate the problem and make it apparent to the observer. The test involves applying a short period of pressure to the joints of the limb before re-examination, and evaluating any change in gait. However, flexion tests rely on the ability of the observer to identify and interpret changes in the horse's gait and in that respect these tests are subjective and not necessarily consistent between observers.
The research study was conducted by orthopaedic surgeons based at the University of Glasgow's School of Veterinary Medicine1. A total of 17 healthy adult horses, all in work, were fitted with sensors before being trotted in a straight line. The sensors measured vertical pelvic movement asymmetry for both right and left hind limb strides and the average difference in maximum and minimum pelvic height between right and left hind limb strides. A hind limb was randomly selected for 60 seconds of proximal flexion, after which the horse was trotted for a minimum of 10 strides. Response to the flexion was blindly assessed as negative or positive by an experienced observer.
John Marshall, lecturer in equine surgery at the University of Glasgow, who led the study, said: "A positive response to flexion resulted in significant changes to objective measurements of pelvic symmetry, supporting the use of inertial sensor systems to objectively assess response to flexion tests."
Professor Jim Moore, North American Editor of the EVJ, said: "The introduction of an objective approach to documenting lameness examination will not only help vets and trainers to investigate equine lameness more accurately. It will also serve as an unbiased method of communicating lameness examination findings among vets, trainers, farriers and other professionals."
The next phase of research will be to establish cut-off values for objective assessment of other equine lameness diagnostic procedures, such as nerve blocks.
Reference
EnteroZoo is a dietary supplement composed of organic mineral and purified water in a gel suspension. Enteromed says it works by binding bacterial toxins as it passes through the animal's digestive tract, thereby helping to maintain a healthy gut and intestinal balance.
Enteromed says that compared to old classic adsorbents, such as clay or charcoal, EnteroZoo can be used long-term and is gentle on an animal's intestines.
The company points to a new in-vitro study from Brighton University School of Pharmacy & Biomolecular Sciences which has shown that EnteroZoo adsorbs E. coli, Shigella and C. difficile toxins1 – common causes of gastrointestinal infection and diarrhoea.
EnteroZoo is suitable for all animals including pregnant and nursing females. It is tasteless and odourless and the company says animals generally accept it without any problems. It can be administered in various ways: directly into the mouth, mixed into feed, put on a treat, mixed in an appropriate amount of water or administered with a plastic syringe into the oral cavity.
For more information, contact: enterozoo@enteromed.co.uk, or visit: www.enterozoo.co.uk
At 9.00am on Thursday and 1.45pm on Friday, Dr Sam Taylor, Feline Specialist and academy lead at the International Society of Feline Medicine (ISFM), will present ‘feline pawsative’, a talk about about cat inappetence and the remedy offered by Mirataz.
At 11.20am on Thursday and 9.00am on Friday, Matt Gurney, clinical director at Anderson Moores will be sharing the latest developments in sedation in dogs including Zenalpha.
At 12.30pm on Thursday and 12.35pm on Friday, Andrew Waller (pictured right), chief scientific officer at Intervacc AB, will be discussing how to rein in the impact of strangles using Dechra’s new protein-based vaccine, Strangvac.
The CPD sessions are first come, first served, and Dechra says it expects the presentations to be well-attended, so it could be worth getting there a little early, although probably no need to pitch a tent outside the night before.
XLEquine and the Animal Health Trust (AHT) have launched Plan, Prevent, Protect, billed as the UK's first equine biosecurity booklet for horse owners and yard managers to work through with their veterinary surgeon, to minimise disease risk on yards and maintain the health and welfare of the horses in their care.
Mark Tabachnik MRCVS, of XLEquine member practice Wright & Morten Veterinary Surgeons said: "For many yard and horse owners, biosecurity is just not on their radar. It only becomes important after they have had an outbreak! Strangles in particular can have devastating effects which impact not only on horse welfare, but the disruption and paralysis of animal movement has significant consequences with relationships on the yard, not to mention the financial costs in some cases.
"We wanted to develop a practical guide that pre-empts these issues by helping owners to set in place simple and in many cases common sense, plans and procedures to prevent a disease outbreak, along with practical steps should the worst happen, and an outbreak occurs.
"Our veterinary farm colleagues and the medical profession are well ahead in terms of biosecurity measures. It's about changing people's mind-sets. For example the NHS "Catch it Bin it Kill it" campaign has been highly successful in adapting our thoughts and actions towards disease spread, and consequently many of us are more aware of the importance of good biosecurity in one way or another."
Dr Richard Newton, Head of Epidemiology and Disease Surveillance at the AHT was also involved in the development of the booklet. He said: "I hope that this will encourage all equine practices to raise their game, it is so important for the whole equine community."
The booklet is available to all equine clients of XLEquine member practices, or it is available to view at http://www.xlequine.co.uk/content/plan-prevent-protect
Merial has announced the launch of a new Blippar app designed to educate horse owners about gastric ulcers.
By using the app - which is available free from the App Store for iPhone or Google Play for Android phones - to scan the company's Gastrogard (omeprazole) adverts, posters or website, clients can watch an educational film with one of the UK's leading specialists in equine ulcers, Richard Hepburn BVSc MS(Hons) CertEM(IntMed) DipACVIM(LA) MRCVS, American and RCVS Specialist in Equine Internal Medicine, demonstrating the signs of ulcers and diagnosis via gastroscopy.
Merial's Equine Marketing and Technical Manager Louise Radford MRCVS said: "With 60% of competition horse and 38% of leisure horses & ponies estimated to have gastric ulcers¹,²,³, it's important that horse owners are aware of the signs of this under-diagnosed condition.
"We know that the number of horses diagnosed and treated for ulcers falls significantly short of incidence levels. We hope that this app will help to raise awareness and prompt more horse owners to consult their vet about gastric ulceration."
A separate Blippar app is also available for horse owners that have been prescribed GastroGard. By scanning the pack, clients can view educational video footage on gastric ulcers, find management tips on treatment and prevention, and set a reminder for future risk periods.
For more information, visit: http://www.equinegastriculcers.co.uk, contact your local Merial equine territory specialist or call Merial Customer Support on 0870 6000123.
Dechra Veterinary Products has launched Ketodale, an anti-inflammatory injection for cattle, horses and swine.
Ketodale contains the non-steroidal anti-inflammatory drug ketoprofen 100mg/ml. It is indicated for use in cattle and swine for diseases associated with inflammation, pain or fever. In cattle these include respiratory diseases, mastitis, osteoarticular and muscular-skeletal disorders, such as lameness and arthritis, and to ease pain post parturition. Ketodale can be used to treat swine suffering from Mastitis Metritis Agalactia (MMA) Syndrome and respiratory tract infections.
In horses, Ketodale is indicated for diseases affecting the osteoarticular and muscular-skeletal system associated with pain and inflammation. These include naviculitis, arthritis and laminitis. It can also be used for post-surgical inflammation and symptomatic therapy of colic and fever.
Ketodale is available in 50ml and 100ml vials.
To coincide with the product's launch, Dechra is carrying out a direct marketing campaign. Practices can take advantage of a special launch offer where they can purchase four vials and get a fifth free. The offer is available for a limited period only.
To find out more about Ketodale, call Dechra on 01743 441 632 or visiting www.dechra.com
VetCell is celebrating a win at Cheltenham, after 'Knowhere' won the Cotswold Chase following pioneering stem cell treatment for a serious tendon injury.
Knowhere had had a good start to his racing career as a four-year-old, winning his first two races as a novice hurdler. But after his second race in 2004 he suffered injuries to both forelimb superficial digital flexor tendons. The left fore showed low grade tendonitis while the right fore had a significant percentage of fibre rupture. As a promising racing prospect, Knowhere’s connections wanted to give him the best possible chance of recovering from his injury so they opted for stem cell therapy. He was treated by Tim Beauregard MRCVS of Summerhill Farm in Gloucestershire.
Bone marrow samples were collected from Knowhere’s sternum and were processed in VetCell's laboratory over a five week period to generate millions of stem cells. Knowhere was sedated, the tendon area was anaesthetised and the leg was then surgically clipped and disinfected. Stem cells, which had been suspended in serum obtained from the original bone marrow sample, were then injected using ultrasound guidance, into the core of the damaged area of the tendon fibres.
For the first week after the implantation Knowhere was kept in his stable to allow the cells to adapt to their new environment. Each day after this he was given walking exercise in order to stimulate the activity of the stem cells, encouraging them to differentiate into tendon cells and form into strong tendon fibres. The amount of exercise was incrementally increased, building up over a three-month period from five minutes each day to 45 minutes twice a day.
By the autumn of 2005 both of Knowhere’s tendons had healed very well and showed good fibre pattern on ultrasonography. He was re-introduced to the racetrack the following year and of the 15 or so races he has been in since, he has finished in the frame on eight occasions and has amassed some £175,000 in winnings.
Vet Tim Beauregard said: “Knowhere’s successful return to the track has been exciting and immensely satisfying to follow and he showed particularly brilliant form in the Cotswold Chase. It remains to be seen whether he will be heading for the Ryanair Chase, the Gold Cup or the Grand National but all involved will be hoping for the best.”
For more information please contact VetCell on +44 207 691 2062 or 866 764 0340, email: info@vetcell.com or visit the website at http://www.vetcell.com/
Dunlops has changed its name to Henry Schein Animal Health.
David Hinton, Managing Director said: "As we change our name to Henry Schein Animal Health, we also reaffirm our company's strong commitment to offer a comprehensive array of products and services to help animal health practitioners in the United Kingdom operate more efficient and successful practices, and provide the best quality patient care.
"We have a new name, but we have the same strong team, the same values, and the same dedication to providing excellent service to our customers."
Henry Schein Animal Health’s expanded offerings include VetLink and Thrive. VetLink is a new e-commerce web site system that enables veterinary surgeons to access the growing internet sector, allowing you to sell anything from pet prescriptions to accessories online, to be delivered to your customers’ homes by Henry Schein Animal Health. Thrive is a new veterinary business analysis service that integrates with practice management software to use a Key Performance Indicator based approach that provides insight into a your practice and identifies areas where you can enhance your business.
The initiative comes after BEVA's new nurse committee ran a survey which found a poor understanding within the profession and amongst clients of what equine nurses can do.
Nurses said they believed they could be given more responsibility and do more within their roles and that there was a lack of opportunity for progression.
BEVA President David Rendle, who is championing this initiative, said: “RVNs are a significant an asset to any equine practice.
“They have invested a lot of time and effort to become highly skilled but in some instances their significant attributes are not being utilised to the full.
“Allowing RVNs to perform the clinical tasks that they are qualified to carry out under Schedule 3 of the Veterinary Surgeons Act 1966, will provide better job fulfilment and career development as well as free up veterinary surgeons to carry out other tasks, all increasing the efficiency of the veterinary team.
“I feel, and the RVN survey results would seem to confirm, that veterinary surgeons and practice managers do not appreciate how much veterinary nurses are allowed to do in equine practice.
"We all know veterinary nurses have the ability; look at what they do in small animal and human nursing, but we have felt unnecessarily constrained by Schedule 3 of the Veterinary Surgeons Act 1966 and the associated RCVS guidelines.
"If you actually look at Schedule 3 it is clear that we can and should be letting our qualified equine nurses do far more.
“There are so many things in equine practice that nurses do better than vets.
"In addition to performing clinical tasks they can add wider value; they are generally (or are perceived by clients to be!) more patient, empathetic and caring so we should utilise these skills and get nurses to take on some of the roles that take more time and require longer client interactions – discussing parasite control programmes, running weight loss clinics, reviewing healthcare plans, making follow-up phone calls and visits to name just a few.
"Nurses can take a lot of pressure off vets and can add a significant revenue stream for the practice.”
On the 9th February, the BEVA will be hosting an online discussion forum for all members of the practice team to discuss the role of nurses and how their skills, experience and knowledge can be better-used.
It's free for BEVA members: https://www.beva.org.uk/Home/Events/BEVA-Events/Event-Details.aspx?eventDateId=1716
Marie Rippingale Chair of the BEVA Nurse Committee said: “Last year’s recruitment and retention survey revealed that 50% of nurse respondents were earning less than £25,000 per annum and 48% of nurses said they were likely to look for a new job in the next two years.
"When asked their top reasons for leaving, salary was the biggest reason, and common themes on what would help the retention of nurses included salary, work-life balance and career progression.
“The review of Schedule 3 is important so we can encourage delegation of tasks to RVNs.
"This will allow RVNs to demonstrate their value and worth, earning money for the practice and achieving job satisfaction at the same time. This will contribute positively towards the current retention crisis.”
To find out more about what equine veterinary nurses can do in practice visit https://www.beva.org.uk/nurses
Photo: Liphook Equine Hospital.
The event is held every four years and hosted alternately by BEVA and the American Association of Equine Practitioners (AAEP).
It offers the opportunity for equine vets to absorb and digest the latest knowledge, clinical practice and scientific advances in the treatment and prevention of colic, from the world’s leading international equine gastroenterology experts.
Held over 2.5 days, the symposium comprises numerous 12-minute oral presentations on a range of topics including surgical techniques, treatment, parasitology, gastric ulceration, endotoxemia, pharmacology of intestinal motility, colic complications, epidemiology, physiology of digestion, the intestinal microbiome and metabolomics.
Each session will be followed by three minutes for questions and discussion.
Poster sessions on the first two days will cover ground beyond the oral presentations and delegates will be able to review and discuss the work with presenters.
There will also be opportunities to network with other equine vets, researchers and professionals.
Clinicians and scientists have until 1 February 2024 to submit abstracts of recent work that they wish to present at this meeting.
The scientific committee will consider abstracts on all aspects of equine gastroenterology, including basic science research and reports of clinical cases or novel approaches to treatment.
The abstract submission form is here: https://form.jotform.com/230473925626359
Tickets cost £475 (with a concessionary rate of £235 for post graduate students and interns) and includes a drinks reception on both 10th & 11th, an evening buffet and Ceilidh on 11th and lunch on 11th & 12th.
Further information and booking details can be found here: https://www.beva.org.uk/Education/CPD/Event-Details/eventDateId/1740
Congratulations to Merial for a creative initiative to celebrate the 25th birthday of Eqvalan®.
The company made a much needed donation towards the upkeep of the Pewsey White Horse in return for being able to use it as part of Eqvalan's birthday celebration publicity programme for 2008.
The money will be used to restore the protective fencing around the ancient landmark, near Marlborough in Wiltshire.
Merial's Claire Parry- Baggott explains: "There are a number of white horse sites across the UK, many of which are extremely popular visitor destinations. To keep these sites open to the public requires year-round maintenance, often from a small army of volunteers.
"Horse owners have been using Eqvalan to help protect their trusty companions for 25 years, and this initiative will help provide protection of a different kind!
"The idea sprang from the current Eqvalan advertising campaign which celebrates 25 years of worming protection. The result is a fantastic 100 feet replica of our Eqvalan birthday horse, and brand new fencing for the Pewsey White Horse!
"We were delighted to help the Pewsey Council raise funds to preserve the site and hopefully this money will enable the horse to be enjoyed by many for years to come," concludes Claire.
A research project funded by The Horse Trust has made important discoveries about how two peptides regulate the inflammatory response in horses. This knowledge could help with the development of improved anti-inflammatory drugs, which are used to treat a wide range of conditions in horses.
The research project was led by Professor Fiona Cunningham at the Royal Veterinary College in Hertfordshire and Dr Karen Rickards at the Donkey Sanctuary in Sidmouth, assisted by Dr Andrew Brooks at the RVC, and by Dr Kirstie Pickles, now at the Royal (Dick) School of Veterinary Studies in Edinburgh.
Inflammation is associated with a wide range of equine diseases, including recurrent airway obstruction, laminitis and sweet itch. Anti-inflammatory drugs, such as glucocorticosteroids, mainly work by blocking the formation and/or actions of compounds produced in the horse's body that cause inflammatory responses. However, these drugs are not always effective and can have unwanted side effects.
This research, funded by The Horse Trust, aimed to find out more about two naturally-occurring peptides - chains of amino acids that are shorter than proteins - known as annexin-1 and CXCL8. Both have been shown to affect the inflammatory response but little research has been done on their effects in horses. In the long term, knowing more about these compounds could help in the development of new anti-inflammatory drugs with fewer side effects.
During inflammation, neutrophils (a type of white blood cell) stick to the cells lining blood vessels and migrate into inflamed tissue, where they ingest and break down harmful agents. Using techniques that mimic these events, CXCL8 was found to cause adherence and migration of horse neutrophils. However, when it was used in combination with another pro-inflammatory substance, neutrophil migration and adherence were markedly decreased. This suggests that attempts to reduce inflammation by blocking the actions of CXCL8 might not be as beneficial as had been thought.
At the start of the project, the researchers had no information about horse annexin-1, other than its gene sequence, so their first step was to develop a method to detect the peptide in white blood cells. They established that it was present and, as horse annexin-1 has not yet been synthesised, they used a synthetic peptide derived from annexin-1, Ac2-26, to look at the effects on horse neutrophils.
They found that Ac2-26 decreased neutrophil adherence and migration in response to other pro-inflammatory compounds, although at high concentrations the peptide itself caused some cell activation, thereby increasing inflammation. They also found that dexamethasone (a glucocorticosteroid) increased the levels of annexin-1 in cells, indicating that, as in humans, this class of drugs is likely to act in part through the formation of annexin-1.
These findings suggest that the use of compounds which mimic the actions of annexin-1 may have limitations as anti-inflammatory drugs. As glucocorticosteroids partly work by forming annexin-1, further research is needed in order to find out how annexin-1 will act in the horse's body and establish how its formation contributes to the beneficial effects of these drugs.
Professor Cunningham said: "This Horse Trust-funded research has resulted in some very interesting findings about how inflammatory cells are regulated in horses. The receptors that annexin-1 and CXCL8 act upon could be targets for new equine inflammatory drugs, but more research is needed first to fully understand their actions and how they produce these effects."
The team's research has been accepted for publication by the journal Veterinary Immunology & Immunopathology.